Revolution Medicines, Inc., a clinical-stage precision oncology company, is revolutionizing cancer treatment through its innovative therapies designed to obstruct frontier targets in RAS-addicted cancers. At the forefront of Revolution Medicines' portfolio is RMC-4630, a promising inhibitor of SHP2, currently in Phase 1/2 clinical trials for the treatment of solid tumors, including gynecologic tumors. In addition to RMC-4630, the biotech firm is also developing RMC-5845, targeted at inhibiting SOS1, a protein that triggers the conversion of RAS (OFF) to RAS (ON) in cells, and RMC-5552, an exclusive inhibitor of mTORC1 signaling in tumors. Moreover, the company is advancing the development of RMC-6291 and RMC-6236, both significant inhibitors of KRASG12C(ON) and multiple RAS(ON) variants, respectively, and RAS(ON) inhibitors designed to target KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. recently sealed a significant partnership in its research and development of SHP2 inhibitors, including RMC-4630, with multinational pharmaceutical company Sanofi. Headquartered in Redwood City, California, the biotech company was established in 2014 and is poised to revolutionize the clinical landscape of cancer treatment.
Revolution Medicines's ticker is RVMD
The company's shares trade on the NASDAQ stock exchange
They are based in Redwood City, California
There are 51-200 employees working at Revolution Medicines
It is revmed.com
Revolution Medicines is in the Healthcare sector
Revolution Medicines is in the Biotechnology industry
The following five companies are Revolution Medicines's industry peers: